Both Casgevy and Lyfgenia are highlighted in a recent Clarivate report among 13 potential “blockbuster and gamechanger” drugs to watch in 2024. AstraZeneca and Ionis add an EU green light to ...
Hosted on MSN11mon
Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's WhyCrispr stock is tumbling for the fifth straight week as the top Cathie Wood's holding struggles amid dimming expectations for its new Vertex-partnered gene-editing drug. Please watch the video at ...
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia. The former is notably the first FDA ...
The FDA approved Lyfgenia and Vertex Pharmaceuticals' (VRTX) Casgevy for the treatment of sickle cell disease in December 2023. Casgevy was co-developed with CRISPR Therapeutics (CRSP).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback